Instil Bio Positioned as a Promising Player in the PD-1/L1 x VEGF Market with Strong Buy Recommendation

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Instil Bio (TIL – Research Report) today and set a price target of $125.00.

Mitchell Kapoor’s rating is based on the strategic positioning and potential of Instil Bio in the competitive landscape of PD-1/L1 x VEGF bispecifics. The recent surge in licensing activities and substantial upfront payments in this sector underscore its significance for large pharmaceutical companies. Notably, Instil Bio’s PD-L1 x VEGF agent has shown competitive clinical data, particularly in China, which positions the company as a promising player in this space.
Furthermore, the recent high-value deals, such as BioNTech’s partnership with Bristol-Myers Squibb and Pfizer’s agreement with 3SBio, highlight the growing interest and potential for significant financial returns in this area. These developments suggest that Instil Bio could become an attractive acquisition target, given its encouraging clinical results. Consequently, Kapoor reiterates a Buy rating, reflecting confidence in the company’s future prospects and its potential to capture a significant market share in the PD-1/L1 x VEGF race.

Kapoor covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Summit Therapeutics, and Cartesian Therapeutics. According to TipRanks, Kapoor has an average return of -22.5% and a 28.99% success rate on recommended stocks.